Unichem Labs.

When is the next results date for Unichem Labs.?

No Upcoming Board Meetings

Has Unichem Labs. declared dividend?

Unichem Laboratories Ltd has declared a dividend of 200%, amounting to ₹4 per share, with an ex-date of August 1, 2022. Despite this, the dividend yield is 0%, and total returns over various periods show strong performance, particularly a 361.69% total return over the last 5 years.

Unichem Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 4<BR>- Ex-date: 01 Aug 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.5%, with a dividend return of 0%, resulting in a total return of -22.5%.<BR><BR>Over the past year, the price return was 13.02%, with a dividend return of 0%, leading to a total return of 13.02%.<BR><BR>In the 2-year period, the price return was 61.13%, with a dividend return of 0%, culminating in a total return of 61.13%.<BR><BR>For the 3-year period, the price return was 144.09%, with a dividend return of 1.72%, resulting in a total return of 145.81%.<BR><BR>In the 4-year period, the price return was 84.11%, with a dividend return of 1.25%, leading to a total return of 85.36%.<BR><BR>Over the last 5 years, the price return was 357.25%, with a dividend return of 4.44%, culminating in a total return of 361.69%.<BR><BR>Overall, Unichem Laboratories Ltd has declared a significant dividend, but the dividend yield remains at 0%. The total returns over various periods show a mix of performance, with particularly strong returns over the longer term, especially in the 5-year period.

Who are the peers of the Unichem Labs.?

Unichem Labs. peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Aarti Drugs, Dishman Carbogen, Gufic BioScience, RPG LifeScience, and Morepen Labs. In terms of management risk, growth, and capital structure, Unichem Labs. is rated as having good management risk, average growth, and good capital structure.

Peers: The peers of Unichem Labs. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Aarti Drugs, Dishman Carbogen, Gufic BioScience, RPG LifeScience, and Morepen Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Gufic BioScience, and RPG LifeScience, while Good management risk is found at Divi's Lab., Torrent Pharma, Aarti Drugs, and Unichem Labs. Average management risk is present at Dishman Carbogen and Morepen Labs. For Growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted at Divi's Lab., Torrent Pharma, Aarti Drugs, and Dishman Carbogen. Unichem Labs. and Gufic BioScience show Average growth, and RPG LifeScience has Below Average growth. In terms of Capital Structure, Excellent capital structure is found at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs., Gufic BioScience, and RPG LifeScience, while Good capital structure is noted at Torrent Pharma, Aarti Drugs, and Unichem Labs. Average capital structure is present at Dishman Carbogen and Morepen Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Aarti Drugs at -3.71%. Unichem Labs. has a 1-year return of 11.97%, which is higher than Aarti Drugs but lower than Divi's Lab. Additionally, Dishman Carbogen and Morepen Labs. have negative six-month returns.

Who are in the management team of Unichem Labs.?

As of March 2023, the management team of Unichem Labs includes Pabitra Bhattacharya (Managing Director), Pranay Godha (Non-Executive & Non-Independent Director), and four Independent Non-Executive Directors: Prafull Anubhai, Anand Mahajan, Prafull D Sheth, and Priti Puri.

As of March 2023, the management team of Unichem Labs includes the following individuals:<BR><BR>1. Prafull Anubhai - Independent Non-Executive Director<BR>2. Anand Mahajan - Independent Non-Executive Director<BR>3. Prafull D Sheth - Independent Non-Executive Director<BR>4. Priti Puri - Independent Non-Executive Director<BR>5. Pranay Godha - Non-Executive & Non-Independent Director<BR>6. Pabitra Bhattacharya - Managing Director<BR><BR>These members contribute to the governance and strategic direction of the company.

What does Unichem Labs. do?

Unichem Laboratories Ltd is an Indian pharmaceutical company that manufactures active pharmaceutical ingredients, with a market cap of INR 4,273 Cr. As of March 2025, it reported net sales of 5,872 Cr and a net profit of 530 Cr.

Overview: <BR>Unichem Laboratories Ltd is an India-based pharmaceutical company that manufactures active pharmaceutical ingredients, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap.<BR><BR>History: <BR>Unichem Laboratories Ltd was incorporated in an unspecified year, and the latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 5,872 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 530 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 4,273 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 31.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.14 <BR>Return on Equity: 5.91% <BR>Price to Book: 1.73 <BR><BR>Contact Details: <BR>Address: Unichem Bhavan Prabhat Estate, Off S V Road Jogeshwari (West) Mumbai Maharashtra : 400102 <BR>Tel: 91-22-66888333 <BR>Email: shares@unichemlabs.com <BR>Website: http://www.unichemlabs.com

Who are the top shareholders of the Unichem Labs.?

The top shareholders of Unichem Labs include Ipca Laboratories Limited with 52.67%, mutual funds holding 9.89% (led by HDFC Small Cap Fund at 7.77%), and individual investors at 14.8%. Foreign Institutional Investors hold 0.98%, and there are no pledged promoter holdings.

The top shareholders of Unichem Labs include several key stakeholders. The majority shareholder is Ipca Laboratories Limited, which holds a significant 52.67% of the shares. Additionally, mutual funds collectively hold 9.89% through 7 different schemes, with HDFC Small Cap Fund being the highest public shareholder at 7.77%. Foreign Institutional Investors (FIIs) hold a smaller portion, with 0.98% across 40 FIIs. Individual investors account for 14.8% of the holdings. There are no pledged promoter holdings reported.

How big is Unichem Labs.?

As of 24th July, Unichem Laboratories Ltd has a market capitalization of 4,536.00 Cr, with net sales of 2,074.06 Cr and a net profit of 144.71 Cr reported in the latest four quarters. The company has shareholder's funds of 2,450.59 Cr and total assets of 3,543.62 Cr for the annual period ending in March 2025.

As of 24th July, Unichem Laboratories Ltd has a market capitalization of 4,536.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Unichem Laboratories reported net sales of 2,074.06 Cr and a net profit of 144.71 Cr.<BR><BR>For the latest annual period ending in March 2025, the company has shareholder's funds amounting to 2,450.59 Cr and total assets of 3,543.62 Cr.

How has been the historical performance of Unichem Labs.?

Unichem Labs has shown significant recovery and growth, with net sales increasing from 1,125.01 crore in March 2020 to 2,110.97 crore in March 2025, and a turnaround in profitability, achieving a profit after tax of 137.52 crore in March 2025 after previous losses. Despite rising total liabilities and negative cash flow from operating activities, the company has demonstrated resilience in its financial performance.

Answer:<BR>The historical performance of Unichem Labs shows a significant recovery and growth in recent years, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Unichem Labs has experienced a steady increase in net sales, rising from 1,125.01 crore in March 2020 to 2,110.97 crore in March 2025. This growth is reflected in total operating income, which also increased from 1,125.01 crore to 2,110.97 crore over the same period. The company's total expenditure, excluding depreciation, rose from 1,263.54 crore in March 2019 to 1,846.11 crore in March 2025, yet the operating profit (PBDIT) improved significantly, reaching 300.18 crore in March 2025, compared to a loss of 7.04 crore in March 2023. Profit before tax turned positive at 154.59 crore in March 2025, recovering from a loss of 176.36 crore in March 2023, while profit after tax also saw a turnaround, achieving 137.52 crore in March 2025 after losses in the previous two years. The company's total assets increased from 3,141.80 crore in March 2020 to 3,543.62 crore in March 2025, with total liabilities also rising from 3,141.80 crore to 3,543.62 crore. Cash flow from operating activities, however, remained negative at -7.00 crore in March 2025, despite a net cash outflow of -65.00 crore for the year. Overall, Unichem Labs has shown resilience and growth in its financial performance, particularly in sales and profitability metrics.

Is Unichem Labs. overvalued or undervalued?

As of November 12, 2025, Unichem Labs. is considered attractive and undervalued compared to peers like Sun Pharma and Cipla, with a PE ratio of 22.88 and a strong 5-year return of 105.39%, despite recent stock performance lagging behind the Sensex.

As of 12 November 2025, the valuation grade for Unichem Labs. has moved from very attractive to attractive, indicating a shift in perception regarding its value. The company is currently assessed as undervalued, particularly in comparison to its peers. Key ratios include a PE ratio of 22.88, an EV to EBITDA of 14.21, and a PEG ratio of 0.05, which suggests strong growth potential relative to its price.<BR><BR>In the peer comparison, Unichem Labs. stands out against companies like Sun Pharma, which has a PE ratio of 35.94, and Cipla, with a PE ratio of 22.56. This positions Unichem Labs. favorably within the industry, especially considering its attractive valuation amidst peers that are deemed expensive. Despite recent stock performance lagging behind the Sensex over the past year, the long-term outlook remains positive, with a notable 5-year return of 105.39% compared to the Sensex's 94.82%.

Is Unichem Labs. technically bullish or bearish?

As of November 17, 2025, Unichem Labs shows a mildly bearish trend, with mixed signals from indicators like the MACD and Bollinger Bands, suggesting a cautious outlook for the stock.

As of 17 November 2025, the technical trend for Unichem Labs has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands and KST both show a mildly bearish trend on both weekly and monthly time frames. Daily moving averages are bearish, and Dow Theory indicates no trend on the weekly but mildly bearish on the monthly. The overall lack of strong bullish signals, combined with the bearish indicators, suggests a cautious outlook for the stock.

Are Unichem Laboratories Ltd latest results good or bad?

Unichem Laboratories Ltd's latest results show a net profit increase of 356.85% year-on-year, but this is largely due to non-operating gains. Revenue declined by 2.24%, and operating margins have significantly compressed, indicating underlying operational challenges and suggesting caution for investors.

Unichem Laboratories Ltd's latest results present a mixed picture. On one hand, the company reported a net profit of ₹264.29 crores for Q3 FY26, which is a remarkable increase of 356.85% year-on-year. However, this figure is largely inflated by exceptional gains, as approximately 80.7% of the profit before tax came from non-operating items. <BR><BR>In terms of revenue, the company experienced a decline of 2.24% year-on-year, with sales dropping to ₹521.17 crores. This decline is concerning, especially as it marks the lowest quarterly revenue for the current fiscal year. Additionally, the operating margin has significantly compressed to 8.59%, down from 16.04% a year ago, indicating ongoing operational challenges.<BR><BR>Overall, while the net profit figure may seem impressive at first glance, the underlying operational performance raises serious concerns about sustainability. The company's reliance on exceptional gains for profitability, coupled with declining revenue and margins, suggests that the results are more troubling than they appear. Investors should approach the situation with caution, as the fundamentals indicate significant challenges ahead.

Should I buy, sell or hold Unichem Laboratories Ltd?

Which are the latest news on Unichem Labs.?

Why is Unichem Laboratories Ltd falling/rising?

As of 15-Apr, Unichem Laboratories Ltd's stock price is rising to 344.00, reflecting a 2.05% increase. This rise is driven by strong short-term momentum and healthy long-term growth potential, despite challenges like a high Debt to EBITDA ratio and low Return on Equity.

As of 15-Apr, Unichem Laboratories Ltd's stock price is rising, currently at 344.00, reflecting a change of 6.9 (2.05%) upward. This increase can be attributed to several factors. Firstly, the stock outperformed its sector by 0.54% today and opened with a gain of 2.05%. Additionally, it reached an intraday high of Rs 353.85, marking a 4.97% increase during the trading session.<BR><BR>In the short term, the stock has shown positive momentum, with a 4.29% increase over the past week and a 6.77% rise over the past month, outperforming the Sensex, which saw a 0.71% increase in the same week and a 4.76% increase over the month. Furthermore, the company has demonstrated healthy long-term growth potential, with an operating profit growth rate of 148.09% annually and a profit increase of 29.9% over the past year, despite the stock's significant decline of 43.72% during that period.<BR><BR>However, it is important to note that while the stock is currently rising, it faces challenges such as a high Debt to EBITDA ratio of 1.95 times, which indicates a low ability to service debt, and a low average Return on Equity of 1.44%. These factors contribute to a mixed outlook for the company, but the recent price increase suggests that investors may be responding positively to its growth potential and current valuation, which is attractive compared to peers.